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1. Introduction  
Fabry disease is a rare disease. However, Fabry disease is more common than other 
inherited lysosomal storage disorders, affecting 1 in 40,000 to 1 in 117,000 worldwide (Mehta 
et al., 2004, Germain, 2010). Fabry disease is the caused by an inherited deficiency of 
galactosylgalactosylglucosylceramidase” (EC 3.2.1.14), commonly referred to as ǂ-
galactosidase A (ǂ-Gal A). As a result, there is progressive cellular accumulation of 
glycosphingolipids, leading to organ failure and premature death. For decades, only 
symptomatic therapy was available, that did not prevent the fatal evolution of the disease. 
In the last decade, two forms of Enzyme Replacement Therapy (ERT), that prevent disease 
progression as well as potentially reverse symptoms, have been developed. However, these 
drugs are expensive and do not cure the disease. 
2. Fabry disease: concept 
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene 
encoding the lysosomal enzyme ǂ-galactosidase A (ǂ-Gal A). ǂ-galactosidase A catalyzes 
the hydrolytic cleavage of the terminal alpha-galactosyl moieties from 
globotriaosylceramide (Gb3) and glycoproteins. The deficiency of ǂ-galactosidase leads to 
accumulation of Gb3 and other glycosphingolipids in plasma and different cell types 
throughout the body (Nance et al., 2006) (Figure 1). Glycosphingolipid storage may interfere 
with cellular membrane proteins, such as ion channels, become cytotoxic, or lead to 
accumulation of soluble cytotoxic metabolites (Schiffmann et al., 2002, Aerts et al., 2008, 
Sanchez-Niño et al., 2010), although the precise molecular link between lipid storage and 
disease manifestations is unclear. Progressive accumulation of Glycosphingolipid is 
associated with systemic disease, with a wide spectrum of clinical manifestations that 
reduce the life expectancy of patients.  
3. Genetics 
The ǂ-galactosidase A gene (GLA) is located on the minus strand of the chromosome X on 
the locus Xq22.1. The GLA gene is 10,223 base pairs long and contains 7 exons. GLA gene 
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may give rise to 7 different processed transcripts by alternative splicing. However, just 




Fig. 1. A) ǂ-galactosidase A catalyzes the hydrolytic cleavage of the terminal galactose from 
globotriaosylceramide (Gb3). B) The deficiency of ǂ-galactosidase leads to accumulation of 
Gb3 and other glycosphingolipids, such as lyso-globotriaosylceramide (lyso-Gb3) 
Within the coding region, 239 single nucleotide polymorphisms present in the general 
population and more than 400 GLA mutations that lead to Fabry disease have been found. 
Exons 5, 6 and 3 comprise the majority of point mutations respectively. Missense mutations 
may be classified in 3 groups in accordance with the effect they have on the protein function 
(Garman & Garboczi, 2004). First, mutations that alter the active site of the enzyme; second, 
mutation that interfere with the correct folding and stability of the protein; and finally, the 
remaining mutations that negatively affect the function of the enzyme. The nature of the 
mutation may influence therapeutic approaches. Most mutations are family-specific, which 
explains the marked variability in the residual enzyme activity and precludes the use of a 
single, fast genetic testing technique. Rather, the whole gene should be sequenced.  
4. Clinical manifestations of Fabry disease 
4.1 Early clinical features 
Although glycolipid accumulation begins in the prenatal period, symptoms of the classic 
form of Fabry disease do not arise until childhood (Vedder et al., 2006). Symptoms include 
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episodes of extremity pain or acroparesthesia, gastrointestinal symptoms, hypohidrosis and 
associated heat sensitivity (Cable et al., 1982; Ries et al., 2005; Rowe et al., 1974) (Table 1). 
Pain has been linked with small fiber neuropathy (Attal & Bouhassira, 1999) and is thought 
to be caused by either reduced perfusion of peripheral nerves or glycosphingolipid 
accumulation in neural or perineural cells (Gadoth & Sandbank, 1983; Gemignani et al., 
1984). Pain has been described as burning and starts in the hands and feet but can radiate 
proximally. It may be present throughout the life of the patient, but frequently peaks in 
childhood or adolescence and then decreases. This has been attributed to end-stage nerve 
injury. Pain may be continuous or episodic, but is triggered by extreme temperature 
changes, fever, stress or physical exercise (MacDermot et al., 2001). Both, acute and chronic 
pains are difficult to deal with medically, requiring the use of narcotic or neuroleptic drugs 
respectively (Schiffmann & Scott, 2002). 
 
Organ system Sign/Symptom 
Nervous system Acroparesthesias 
 Nerve deafness 
 Heat intolerance, hypohidrosis 
 Hearing loss, tinnitus 
Gastrointestinal tract Nausea, vomiting, diarrhea 
 Postprandial bloating and pain, early satiety 
Skin Angiokeratomas 
Eyes Corneal and lenticular opacities 
 Vasculopathy (retina conjunctiva) 
Kidneys Microalbuminuria, proteinuria 
 Impaired concentration ability 
Heart Impaired heart rate variability 
 ECG abnormalities (shortened PR interval) 
 Mild valvular insufficiency 
 Left ventricular hypertrophy 
Table 1. Early signs and symptoms of Fabry disease 
Gastrointestinal manifestations include nausea, vomiting, abdominal pain, early satiety, 
diarrhea and constipation (Hoffmann & Keshav, 2007). It has been proposed that delayed 
gastric emptying, in conjunction with lipid accumulation within ganglion cells of the 
autonomic nervous system, are responsible for the early satiety, whereas diarrhea has been 
linked to bacterial overgrowth (O’Brien et al., 1982). 
Decreased sweating or hypohidrosis is another common feature of Fabry disease. It causes 
heat intolerance and inability to physical exercise. Hypohidrosis has also been attributed to 
autonomic neuropathy (Zarate & Hopkin, 2008). Less frequent than hypohidrosis is 
hyperhidrosis (excessive sweating), which is especially noticeable in the palms of the hands 
and soles of the feet (Zarate & Hopkin, 2008). 
These symptoms highly reduce the quality of life of patients. However, the lack of physical 
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More characteristic disease manifestations arise in adolescence, such as angiokeratomas and 
corneal opacities. Angiokeratomas are reddish-purple vascular skin lesions, usually 
clustered around the swimming trunk region, which tend to increase in size and number 
with age (Zarate & Hopkin, 2008).  
Corneal opacity (cornea verticillata) is the most characteristic ophthalmological abnormality 
observed in Fabry patients. They are the result of glycosphingolipids deposition between 
the basal membrane of the corneal epithelium and Bowman’s membrane (Rodríguez-
González-Herrero et al., 2008). Corneal opacities usually do not interfere with visual acuity. 
Other ophthalmological manifestations include conjunctival and retinal vascular tortuosity 
(Nguyen et al., 2005) and occlusion of retinal vessels (Utsumi et al., 1997).  
Later in life many patients develop life-threatening complications including end-stage renal 
disease, heart and cerebrovascular diseases that may cause death (Table 2).  
 
Organ system Sign/Symptom 
Central nervous system Stroke 
Kidneys End-stage renal disease 
  
Heart Arrythmia, sudden death 
 Ischemis 
 Heart failure 
 Heart fibrosis 
Table 2. Life threatening signs and symptoms of Fabry disease 
4.2 Life-threatening complications 
Classical Fabry disease progresses to irreversible tissue damage and organ dysfunction, 
limiting life-expectancy in middle-age patients (Zarate & Hopkin, 2008). The main cause 
leading to death in men suffering from classic Fabry disease was renal failure before the 
widespread availability of renal replacement therapies, while now cardiac causes 
predominate (Mehta et al., 2006.). 
Renal abnormalities include proteinuria, nephrotic range proteinuria, rarely nephrotic 
syndrome and chronic renal failure, requiring dialysis or kidney transplantation (Branton et 
al., 2002; Tsakiris et al., 1996, Ortiz et al., 2008, Ortiz et al., 2010)  
Some patients develop end-stage renal disease at the same age as those with the classic form 
but lack other characteristic signs of the classical phenotype such as angiokeratomas, 
acroparesthesias or hypohidrosis, thus hindering the diagnosis of the condition (Nakao et 
al., 2003).  
Cardiac disease may have several clinical manifestations. (Patel et al, 2011) The most frequent 
cardiac abnormality is progressive hypertrophic cardiomyopathy, although diastolic 
dysfunction, arrhythmia, myocardial fibrosis and short P-R are also seen (Linhart & Elliott, 
2007). Fabry patients are frequently hypotensive. However, Fabry patients may have blood 
pressure that may be above recommended targets for chronic kidney disease patients 
(which are below 130 mmHg systolic and below 80 mmHg diastolic) (Ortiz et al., 2008). 
Cardiac symptoms may include palpitations, angina, shortness of breath and sudden death 
(Shah & Elliott, 2005).   
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The mechanisms leading to myocardial hypertrophy are not completely understood. The 
fact that only 1-2% of heart hypertrophy is attributable to actual storage of 
glycosphingolipids within the cardiac cells suggests that activation of signaling pathways 
leading to fibrosis play an important role (Linhart & Elliott, 2007). In this regard, much of 
the heart volume consists of fibrosis. Actual promoters of fibrosis are unknown. However, if 
we take a clue from the kidney, both death of myocardial cells and the presence of 
fibrogenic soluble mediators, such as lyso-gb3, that promote release of transforming 
growth factor beta 1 (TGFβ1), a fibrogenic cytokine, may be contributors (Sanchez-Niño et 
al, 2010). 
A cardiac variant of Fabry disease has been described. In these patients, clinical 
manifestations and Gb3 storage are almost restricted to the heart (Ogawa et al., 1990). This is 
associated with residual ǂ-galactosidase A activity or certain mutations. There is no clinical 
evidence of classical Fabry disease in other organs, although mild proteinuria has been 
observed (Ishii et al., 2002). Clinical manifestations appear later in life than in classical Fabry 
disease. 
Cerebrovascular complications, mainly ischemic episodes, occur in Fabry disease (Sims et al. 
2009). This is thought to be due to the accumulation of Gb3 in the cerebral blood vessels 
(Altarescu et al., 2001). However, the effect of sphingolipid storage is different depending on 
vessels’ diameter. Thus, Gb3 deposition leads to progressive stenosis in small blood vessels, 
whereas in larger vessels weakened walls dilate, causing hyper-perfusion and tortuosity 
(Mitsias P, 1996). Clinical consequences of cerebrovascular injury include stroke, transient 
ischemic attacks, epilepsy, vertigo and headache (Mehta & Ginsberg, 2005).  
Arterial remodeling and intima-media thickening have been described and may explain 
ischemic events. By contrast, classical atherosclerotic lesions are uncommon. It is unclear 
whether this is due to the relative young age of most patients or to a specific change in the 
vascular response to injury brought about the glycolipid accumulation or the metabolic 
consequences of the disease. In this regard, high HDL cholesterol levels have been described 
in Fabry patients (Cartwright et al., 2004). In at least in some Fabry patients HDL particles 
contribute disproportionately to carry glycosphingolipids (Clarke et al., 1976). 
4.3 Other clinical manifestations 
Additional clinical manifestations may include anemia, azoospermia, depression, facial 
dysmorphism, hypothyroidism, lymphoedema, parapelvic kidney cysts and priapism (Ries 
et al., 2004, Sunder-Plassmann, 2006), although there is discussion whether some of these, 
such as hypothyroidism, are real Fabry disease manifestations. 
Tinnitus and substantial hearing loss have been described, especially in men (Hegemann et 
al., 2006). Hearing loss seems to be directly related to neuropathy (Ries et al., 2007). 
Significant airflow reduction is common in Fabry patients. Respiratory involvement 
manifests as shortness of breath and dyspnea with exercise, chronic cough, and less 
frequently asthma (Rosenberg et al., 1980).  
4.4 Fabry disease in women 
Traditionally females were considered to be at low risk of clinical manifestations of Fabry 
disease. However, there is accumulating evidence that some females may suffer symptoms 
as severe as males (Wilcox et al., 2008). In this regard, Fabry disease may be considered as an 
X-linked disease with a high penetrance in females. Terms such as “recessive X-linked 
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disease” are no longer used. It has been estimated that only 70% of women with GLA 
mutations develop clinical manifestations of the disease, which tend to be less severe and 
more variable than in men (Dobyns, 2006, Schiffmann R, 2009). As a result, it is likely that a 
large number of affected women remain undiagnosed. Women are affected because of the 
lack of cross-correction between cells with normal ǂ-Gal A activity and cells with deficient 
ǂ-Gal A (Romeo et al., 1975). Female cells have two X chromosomes, but one of them is 
randomly inactivated (lyonization). It is thought that the percentage of disease-carrying X 
chromosomes that are inactivated is a key factor contributing to disease expression 
variability in females (Dobrovolny et al., 2005). 
5. Fabry nephropathy 
5.1 Natural course 
Fabry nephropathy is one of the most severe manifestations of Fabry disease and was the 
cause of death before the widespread availability of dialysis and kidney transplantation. 
Like most aspects of Fabry disease, kidney disease is thought to result from Gb3 
accumulation in glomerular endothelial, mesangial and intersticial cells, podocytes and 
renal vasculature. Progressive intracellular accumulation of Gb3 is thought to cause 
glomerulosclerosis and interstitial fibrosis (Alroy J, 2002) as well as its urinary excretion 
together with other lipids (Branton MH, 2002). More recently a role of soluble glycolipid 
metabolites in the pathogenesis of podocyte injury has been suggested (Sanchez-Niño et al, 
2010). As a result of lipid storage, kidneys may increase in size, although, as is the case with 
other renal disease characterized by enlarged kidney, such as diabetic nephropathy, in 
advanced renal failure the kidneys eventually shrink (Torra R, 2008).  
Manifestations of kidney injury in Fabry disease include urinary concentrating defect, 
proteinuria, renal insufficiency and eventually renal failure requiring renal replacement 
therapy. The severity of kidney manifestations increases with age. 
5.1.1 Renal function 
Progressive loss of kidney function is characterized by elevated serum creatinine levels and 
decreasing glomerular filtration rates (GFR) (Ortiz et al, 2008). There is some debate as to the 
existence of an early hyperfiltration period, analogous to that observed in diabetic 
nephropathy, since assessment with of GFR by precise, research-grade technique is lacking. 
Early reports indicated that the loss of GFR was similar to that observed in diabetic 
nephropathy, around 10 ml/min/year (Branton et al., 2002). Lower rates have been 
described in recent times, that may be partially attributed to an overall better symptomatic 
control of chronic kidney disease aimed at proteinuria and blood pressure targets. Urinary 
protein excretion is the main predictor of GFR loss. Males with urinary protein/creatinine > 
1.5 had a mean eGFR slope -5.6 ml/min per 1.73 m(2) per year, while this value was -1.3 
ml/min per 1.73 m(2) per year for women with the highest urinary protein/creatinine (> 
1.2) (Wanner et al., 2010). 
Men with classical Fabry disease reach end-stage renal disease requiring dialysis or 
transplantation at a mean age of 40 years (Ortiz et al, 2010). Females reaching end-stage 
renal disease do so at the same mean age as males. However, there are ten-fold less females 
than males in both United States and European end-stage renal disease registries (Tsakiris et 
al., 1996, Thadhani et al, 2002). This suggests that in most females, Fabry nephropathy does 
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not progress to reach end-stage renal disease, but in those in whom progression occurs, the 
time-course is similar to males. 
5.1.2 Proteinuria 
Early kidney injury is manifested as microalbuminuria which progresses to overt 
proteinuria (Schiffmann, 2009, Ortiz et al, 2008). Microalbuminuria is a misnomer that only 
indicates that pathological abnormalities may be detected by methods not available when 
the first tests to study albuminuria were commercialized. The term microalbuminuria 
indicates a urinary albumin excretion of > 30 mg/24h or >30 mg/g creatinine. In this regard, 
Fabry nephropathy usually recapitulates the sequence of events observed in diabetic 
nephropathy, another proteinuric nephropathy also consequence of a metabolic 
derangement. Overt proteinuria (>300 mg/24 h) was present in 43 and 26% of males and 
with early Fabry disease, respectively, and the proportions were higher with more severe 
kidney involvement (Ortiz et al, 2008). Established proteinuria (Albuminuria > 300 mg/day) 
is a sign of irreversible damage to the kidney (Zarate & Hopkin, 2008). Numerous 
experimental studies have shown a direct relationship between the degree of proteinuria 
and the rate of decline of renal functions (Tryggvason & Pettersson, 2003). Proteinuria is a 
consequence of glomerular damage but itself causes tubulointerstitial injury. Reabsorption 
of excess specific proteins filtered at the glomerulus by the proximal tubule activates these 
cells to release inflammatory factors and undergo apoptosis (Thomas ME, 1999). Thus, the 
magnitude of proteinuria could be used as a marker of glomerular damage. Interestingly, 
morphological studies, not specifically performed in Fabry disease, have confirmed a 
stronger correlation between tubulo-interstitial damage and renal function than between 
glomerular injury and renal function (Nath, 1992). Little is known about the factors that may 
speed up the process of Fabry nephropathy. Proteinuria is clearly a risk factor (Wanner et 
al., 2010). Thus, controlling proteinuria is thought to be important to for the progression of 
Fabry disease and evidence for this approach is discussed below. 
5.1.3 Blood pressure 
Hypertension is rarely found as an early symptom in Fabry disease but becomes more 
prevalent with the progression of the condition, indicating kidney declining function 
(Branton et al., 2002). Higher blood pressure values favor glomerular hyperperfusion as a 
compensatory response to nephron loss (Schieppati & Remuzzi, 2003). However, glomerular 
hypertension promotes kidney disease progression. Although not specifically tested in 
Fabry disease, lowering blood pressure to below 130 mmHg systolic AND 80 mmHg 
diastolic is recommended in patients with chronic kidney disease in order to slow the 
progression of nephropathy (K/DOQI clinical practice guidelines, 2004). 
5.2 Heterogeneity 
There is a great variability both in disease manifestations and the timing of kidney disease 
progression within and between families. Thus, the age at initiation of renal replacement 
therapy in the Fabry Registry data had a range of 15 to 79 years in males and 17 to 78 
years in females (Ortiz A et al., 2010). The genetic or environmental factors that influence 
disease heterogeneity are unknown. However, unraveling them is a key priority since it 
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5.3 Women 
Most heterozygous women with Fabry disease used to be considered asymptomatic carriers. 
However, they may be as severely affected as men with the classic phenotype (Desnick et 
al., 2001, Wang et al., 2007, Wilcox et al., 2008). The clinical manifestation of Fabry disease in 
females tend to be less severe and to arise later than in males (Schiffmann. 2009). In this 
regard they may develop albuminuria and progressive renal dysfunction leading to the 
need of renal replacement therapy (Ortiz et al., 2008; Ortiz et al; 2010). If this occurs the 
mean age at initiation of renal replacemebt therapy is similar to men (Ortiz et al, 2010).  
5.4 Diagnosis 
In spite of the early onset of Fabry disease in some cases, the absence of family history, the 
variety of clinical manifestations and their similarity with those of other conditions may 
delay the diagnosis of Fabry disease, in some cases for years. Due to the availability of 
specific therapy, an early diagnosis would be desirable. 
5.4.1 Diagnosis of Fabry disease 
Diagnosis involves measuring residual enzyme activity in plasma, leukocytes or whole 
blood as well as sequencing of the gene to characterize the genetic defect (Ortiz et al., 2010b). 
Confirming the genetic defect may be important for the eligibility for treatment with novel 
approaches, such as chaperones. In the absence of family history, confirmation of the genetic 
defect by gene sequencing is mandatory in females when Fabry disease is suspected, since 
enzymatic assays may be normal even in the presence of Fabry disease due to random 
chromosome X inactivation. Genetic confirmation is also highly recommended in males. 
A key, often forgotten aspect of Fabry disease, is the need to take a careful family history 
which allows the diagnosis of individuals in early stages of the disease.  
5.4.2 Screening for Fabry disease 
Screening by means of rapid and low-cost strategies to detect Fabry disease is indicated in 
high-risk populations (Oqvist et al., 2009). These include patients with unexplained left 
ventricular hypertrophy, younger patients with unexplained stroke and patients with 
chronic kidney disease of unknown etiology. However, neonatal screening has not yet been 
incorporated into routine clinical practice. Current screening methods are based on 
quantification of enzyme activity in dry blood spots. Performance for males is adequate. 
However, given the mosaicisms of females regarding X chromosome inactivation, Fabry 
women may have near normal whole blood enzyme activity and still have the disease. Thus, 
dried blood spot analysis is unable to detect about a 33% of heterozygous females leads to 
the need for more efficient strategies (Linthorst GE, 2005). Novel screening methods, such as 
proteomic analysis of urine, and quantification of urinary Gb3 or lyso-Gb3 are under study.  
5.4.3 Renal biopsy for diagnosis of Fabry nephropathy 
Kidney biopsy is recommended in Fabry patients exhibiting reduced GFR or proteinuria to 
confirm the diagnosis of Fabry kidney involvement (Ortiz et al., 2008b). In addition, renal 
biopsy for kidney disease of unknown origin may reveal unsuspected Fabry disease. 
Biopsies reveal typical Gb3 accumulation in tubular epithelial cells, glomerular and 
endothelial cells, and provide information on the extent of renal damage. In patients with 
Fabry disease, glomeruli present a striking white color under illumination in a 
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stereomicroscope as a result of lipid-laden podocytes in contrast to the usual red color of 
normal glomeruli (Svarstad et al., 2004). 
5.5 Pathogenesis and pathology 
Fabry disease manifestations had traditionally been ascribed to intracellular accumulation of 
Gb3 and related glycosphingolipids (Figure 1). However, the precise pathways leading to 
tissue injury were unknown. Recent evidence suggests a role for more soluble molecules, 
such as lyso-Gb3, that may activate target tissue cells, such as podocytes, to release 
secondary mediators of injury that would be responsible for tissue injury and disease 
manifestations (Figure 2).  This model (accumulation of a soluble metabolite with cytotoxic 
properties) would be analogous to the diabetes situation, where high glucose concentrations 
as a result of the metabolic derangement promote activation of target tissue cells to release 
mediators that cause tissue injury. If correct, this paradigm would greatly enhance research 
into novel therapeutic approaches to Fabry nephropathy by allowing the extrapolation of 
concepts from diabetic nephropathy, a better understood and more common disease 
(Sanchez- Niño et al., 2010b).  
 
 
Fig. 2. Hypothetical similarities between the pathogenesis of diabetic nephropathy and 
Fabry disease nephropathy and potential therapeutic implications 
Detailed descriptions of kidney pathology in children and adults with Fabry disease have 
recently been published (Tondel et al., 2008, Fogo et al., 2010, Najafian et al., 2010). There is 
widespread glycolipid accumulation in glomerular podocytes, mesangial and endothelial 
cells, as well as proximal and distal tubular cells, interstitial endothelial cells and other 
endothelial cells. While early pathogenic theories were centered in endothelial cell 
glycolipid accumulation, that was thought to lead to ischemic injury, the total early 
clearance of endothelial deposits by ERT, but persistence of proteinuria and chronic kidney 
disease progression despite this endothelial clearance have focused the attention to 
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glycolipid clearance (Germain et al, 2007). Only after 5 years of ERT a mild decrease in 
podocytes glycolipid deposition was noted. Furthermore, podocyte injury is a key feature of 
other proteinuric kidney diseases (Moreno et al., 2008). In addition, in children with early 
Fabry nephropathy the best pathological correlate of albuminuria was the presence and 
amount of podocytes glycolipid accumulation (Najafian et al., 2010). Thus, recent research 
into the pathogenesis of Fabry nephropathy has focused on the cell biology of the podocyte 
(Sanchez-Niño et al., 2010). The other key pathology feature of Fabry nephropathy is 
glomerular (glomerulosclerosis) and interstitial fibrosis, which is associated with loss of 
parenchymal renal cells (podocytes and tubular cells)(Fogo et al., 2010). Thus, there is 
renewed interest in the link between metabolites accumulated in Fabry disease and the 
synthesis and deposition of extracellular matrix components.  
5.5.1 Metabolic initiators: Gb3 and lyso-Gb3 
In Fabry disease, Gb3 is widely distributed in lysosomes and other cellular compartments 
such as the cell membrane, the ER or the nucleus (Askari et al., 2007). It was hypothesized 
that Gb3 may disrupt intracellular trafficking (Pagano RE, 2003) or alter the composition of 
membrane lipid rafts. Lipid rafts interact with other lipids and proteins that signal from cell 
surface receptors (Galbiati et al., 2001), such as endothelial nitric oxide synthase (eNOS) 
(Mogami et al., 2005). It was further hypothesized that cell stress due to Gb3 accumulation 
could promote the production of reactive oxygen species (ROS) that induce cell death (Shen 
et al., 2008).   
Although Gb3 accumulation is widespread, serum Gb3 or Gb3 deposits do not necessarily 
correlate with clinical manifestations (Aerts et al., 2008). Instead, a new biologically active 
soluble glycolipid metabolite, globotriaosylsphingosine (lyso-Gb3), has been found in high 
serum, kidney and urinary concentrations in Fabry patients (Aerts et al., 2008, Auray-Blais 
et al., 2010, Togawa et al.2010b). Lyso-Gb3 is involved in vascular smooth muscle cell 
proliferation and induces in podocytes the production of mediators of glomerular injury 
such as TGF-ǃ1, a critical mediator of extracellular matrix (ECM) production, fibrosis and 
podocyte injury (Alsaad & Herzenberg, 2007; Mason & Wahab, 2003; Pantsulaia. 2006; Park 
et al., 1997) (Sharma et al, 1997)  and CD74, a MIF receptor that regulates the expression of 
lethal cytokines (Sanchez-Niño et al., 2009), suggesting a role in the pathogenesis of Fabry 
disease (Sanchez-Niño et al., 2010). 
Lyso-Gb3 seems to be involved in glomerular injury in Fabry disease by triggering the 
release of TGF-beta1 and CD74, both secondary mediators of glomerular injury common to 
diabetic nephropathy (Sanchez-Niño et al., 2010). TGF-beta1, in turn, leads to release of 
excess ECM components, including type IV collagen and fibronectin, by podocytes, 
contributing to the characteristic glomerulosclerosis of Fabry nephropathy. Further 
unpublished data suggest a more widespread release of inflammatory mediators by 
podocytes exposed to lyso-Gb3.  
5.6 Therapy of Fabry nephropathy 
The first therapies for Fabry disease were oriented to deal with the symptomatic effects of 
the disorder, such as pain, cardiac and cerebrovascular complications. However, most 
patients would die for ESRD unless kidney transplantation or renal dialysis was applied. 
Guidelines for the management of Fabry nephropathy have recently been published (Ortiz 
et al., 2008b). 
www.intechopen.com
 
Fabry Disease: A Metabolic Proteinuric Nephropathy 265 
5.6.1 Enzyme replacement therapy (ERT) 
Until 2000, recognition of Fabry disease did not change the patient management or 
prognosis, since no specific treatment was available. However, in the last decade enzyme 
replacement therapy (ERT) is available and addresses the metabolic defect, although it does 
not cure the disease. ERT provides the chance to modify the natural history of Fabry disease. 
Two companies commercialize human recombinant ǂ-galactosidase synthesized by 
genetically engineered cell lines. 
Indications: ERT is indicated in every male with classical Fabry disease. In this population 
ERT should be initiated as early as possible. In addition, ERT should be prescribed to 
females with any evidence of injury to the heart, central nervous system or kidney and 
considered in females with symptoms in other organs and systems (Germain DP, 2010, Ortiz 
et al., 2010b). In case of a transitory limitation in ERT supplies, prioritization guidelines have 
been published (Linthorst et al., 2011). These guidelines should not be considered 
compelling indications in the absence of limited availability of treatment. Furthermore, 
these guidelines do not apply to a chronic limitation of resources since they take into 
account both the indication of ERT as well as the urgency of the need of ERT. Thus, they 
do not answer the question who should and should not be treated. They answer the 
question, if therapy is indicated but ERT availability is limited, who should be treated 
first, implying that not prioritized patients will also be treated but later, as soon as 
supplies are available. 
There are currently two commercially available enzyme preparations for the treatment of 
Fabry disease: (1) Replagal® (agalsidase alfa; Shire Human Genetic Therapies, Inc., 
Cambridge, MA) and (2) Fabrazyme® (agalsidase beta; Genzyme Corporation, Inc., 
Cambridge, MA). Algasidase alfa is produced by cultured human fibroblasts, whereas 
agalsidase beta produced by the expression of human a-galactosidase cDNA in Chinese 
Hamster Ovary (CHO) cells. In the USA, only agalsidase ǃ has been approved by the US 
Food and Drug Administration, while in Europe both enzymes are available for clinical 
use.  
The approved doses of agalsidase-alfa and agalsidase-beta are 0.2 mg/kg and 1.0 mg/kg, 
given intravenously every 2 weeks, respectively. There is evidence that agalsidase-beta may 
be used at 0.3 mg/kg every two weeks for certain patients. This difference in dose remains 
unexplained by the molecular nature of the preparations and there is an ongoing debate 
whether they are similarly effective. The only published head-to-head clinical trial 
concluded that disease progression occurred when both enzymes where used at a dose of 
0.2 mg/kg every two weeks (Vedder et al, 2007). We must emphasize that this dose is the 
approved one for agalsidase-alfa, but was 5-fold lower than the approved dose for 
agalsidase-beta. There is some indication, although the evidence is not strong, for a 
superiority of the higher dose in patients who develop anti-agalsidase antibodies. 
Furthermore a doubling of the approved agalsidase alfa dose provided further benefit in 
terms of nephroprotection for patients whose disease was progressing despite treatment 
with the approved dose. In addition, only agalsidase beta has shown a benefit on hard end-
points in a phase IV randomized clinical trial (Banikazemi et al., 2007). Despite these 
considerations, a number of publications have documented that both enzymes at approved 
doses have proved effective in reducing glycolipid deposits and disease manifestations at 
least if used early (Eng et al, 2001, Schiffmann et al., 2001; Schiffmann et al., 2006; Germain et 
al., 2007; Mehta et al., 2009; Schaefer et al., 2009). 
www.intechopen.com
 
Advances in the Study of Genetic Disorders 266 
5.6.2 Benefits and unmet needs of ERT 
ERT addresses the underlying metabolic cause of Fabry disease. ERT slows the loss of 
kidney function in patients with relatively preserved renal function and low proteinuria 
(Schiffmann et al., 2006) (Germain et al., 2007). However, progression occurs despite ERT in 
patients with more advanced renal disease, including those with proteinuria> 1g/d or 
glomeruloscerotic lesions in renal biopsyl, as ERT does not reduce proteinuria and may be 
unable to avoid its development in treated pediatric patients (Tøndel et al., 2008). Thus, 
since proteinuria is a major risk factor for progression of Fabry disease, it is advisable to 
combine antiproteinuric therapy with early institution of ERT.  
5.6.3 Antiproteinuric approaches 
ACEI/ARBs: the lesser efficacy of ERT once Fabry nephropathy has caused proteinuria or 
glomerulosclerosis (Germain et al., 2007) raises the need for adjuvant therapies  
that cooperate with ERT in improving outcomes. Co-treatment with angiotensin-
converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARB) decreases 
proteinuria (Tahir et al., 2007). These agents help to control hypertension when present, 
although in some case a low blood pressure may limit their use. To prevent unwanted 
blood pressure lowering effects initiation of therapy with low, fractionated doses is 
recommended.  
Active vitamin D has pleiotropic effects that go well beyond the regulation of bone 
metabolism (Rojas-Rivera et al., 2010). Vitamin D receptor (VDR) activators such as calcitriol 
and paricalcitol prevent podocyte activation by lyso-Gb3 in podocytes (Sanchez-Niño et al., 
2010). In this regard, there is some evidence that paricalcitol, a selective VDR activator, 
reduces proteinuria in diabetic nephropathy, even in patients treated with ACEIs or ARBs 
(Agarwal et al., 2005; Lambers Heerspink et al., 2009; de Zeeuw et al., 2010). Interestingly, 
patients suffering from chronic kidney disease frequently have deficiencies of both 25(OH) 
vitamin D and calcitriol. Vitamin D deficiencies should be corrected in these patients and 
VDR agonists are indicated for the prevention and treatment of secondary 
hyperparathyroidism in chronic kidney disease (Kidney Disease: Improving Global 
Outcomes (KDIGO) CKD-MBD Work Group. 2009) (National Kidney Foundation. 2003). 
Thus, VDR agonist therapy used to treat vitamin D deficiency or secondary 
hyperparathyroidism might be beneficial for proteinuria in Fabry disease. 
5.6.4 Novel therapies in the horizon 
The search for an ideal treatment of the underlying enzymatic defect is still ongoing. 
Current ERT is expensive, inconvenient and may not reach certain key cells such as the 
podocytes. Additional therapeutic approaches are being explored. 
Substrate reduction therapy by small molecules may be associated with ERT to improve 
efficacy or reduce ERT dose. Gene therapy is also being explored. In addition certain 
mutations may benefit from novel therapeutic strategies. Thus, individuals carrying 
mutation that interfere with the correct folding and stability of the protein may benefit from 
small molecule chaperone therapy. In addition, an orally active small molecule, ataluren, 
might be useful in individuals carrying premature stop codons (Torra et al. 2010). Although 
never tested in Fabry disease, clinical trials in other genetic diseases are underway or have 
been completed (Kerem et al., 2008). 
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5.6.5 Monitoring therapy and disease progression 
We lack reliable biomarkers that enable assessing disease progression, monitoring treatment 
response and individualizing ERT dose in Fabry disease. Biomarkers may represent lipid 
storage burden or target organ injury or response to therapy. Potential biomarkers of 
glycolipid storage include plasma or urine Gb3 and lyso-Gb3. Lyso-Gb3 plasma and urinary 
levels are elevated in Fabry disease. Plasma lyso-Gb3 was found to be useful to diagnose 
Fabry disease (Rombach et al., 2010). Furthermore, while multiple regression analysis did 
not demonstrate correlation between plasma lyso-Gb3 concentration and total disease 
severity score in Fabry males, plasma lysoGb3 concentration did correlate with white matter 
lesions. In addition, in females, plasma lyso-Gb3 concentration correlated with overall 
disease severity (Rombach et al., 2010). In Fabry patients plasma lyso-Gb3 falls on ERT, and 
even more dramatically than Gb3 levels (Togawa et al., 2010, Van Breemen et al., 2011). 
Urinary lysoGb3 was also correlated with type of mutations, enzyme replacement therapy 
status and with a number of indicators of disease severity (Auray-Blais et al, 2010). 
Decreased urinary lyso-Gb3 may reflect decreased kidney lyso-Gb3 burden, since renal 
tissue lyso-Gb3 was decreased in Fabry mice upon ERT (Togawa et al., 2010b). Despite these 
promising observations, studies approaching the potential value of lyso-Gb3 concentrations 
to make clinical decisions regarding ERT dose have not been performed and, thus, it cannot 
be considered a biomarker for such purpose.  
Albuminuria is a biomarker of kidney injury. Both in Fabry and non-Fabry kidney injury the 
magnitude of albuminuria predicts renal disease progression. In this regard there is solid 
evidence supporting targeting albuminuria as a therapeutic objective in non-Fabry disease. 
Anecdotal evidence suggests that this is the case too in Fabry disease, where lowering 
albuminuria is considered a target to be pursued through adjunctive antiproteinuric therapy 
(Tahir et al., 2007). A clinical trial (FAACET) is underway to test this hypothesis. 
Unfortunately, since albuminuria does not improve on ERT in adults, it cannot guide ERT 
dosing. 
Finally promising preliminary data are available of the use of urinary protemics for the 
diagnosis and eventual monitoring of Fabry disease. The most promising technique is 
capillary electrophoresis coupled to mass spectrometry (CE-MS) (Mischak H et al., 2010). 
6. Conclusions 
Research in Fabry disease is very active in recent times and has led to a paradigm shift in 
our understanding of the disease and its management (Table 3). The advent of ERT has 
changed the prospects for Fabry disease patients. However, there are, still unsolved 
problems: 
1. ERT does not modify proteinuria, a key risk factor for renal disease progression 
(Wanner et al., 2010), in adults and does not stop renal disease progression once a 
certain degree of renal injury, manifested as histological injury, decreased eGFR or 
proteinuria (>1g/d), has been reached (Germain DG et al., 2007). 
2. Despite adequate endothelial cell clearance, ERT does not clear deposits in podocytes, 
key cells responsible for avoiding proteinuria (Germain DG et al., 2007). This and the 
correlation of early podocyte injury with proteinuria (Najafian et al., 2010) support a 
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3. The lack of biomarkers of tissue injury activity and response to therapy hinders dose 
individualization, the follow-up of the therapeutic response and early identification of 
females most at risk for progressive disease. 
4. The molecular link between the metabolic defect and tissue injury is still poorly 
characterized. This hinders the development of adjuvant therapies. 
The full scope of these gaps in knowledge became evident during the global shortage on 
ERT availability, which took place in 2009-2010 (Linthorst et al, 2011). Hopefully this 
realization, as well as recent advances in the pathogenesis and treatment approaches for the 
disease will further improve the outcome of Fabry patients. 
 
Classical concepts New paradigms 
Endothelium as key target cell Podocyte as key target cell 
Intracellular deposits cause injury Soluble metabolites cause injury 
Deposits injure cells containing them Injury of distant or adjacent cells 
Unknown tissue injury mechanisms Recruitment of secondary mediators 
ERT as only therapy Need for adjuvant therapies 
Same dose fits all Individualize dose: biomarkers need 
Therapeutic nihilism for advanced tissue 
injury 
Target secondary mediators of injury in 
advanced tissue injury 
Table 3. Classical concepts and new paradigms in Fabry nephropathy 
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